ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1100

Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine

Aranzazu Mediero1,2, Patricia Llamas3, Sergio Portal-Nuñez4, Raquel Largo5, Gabriel Herrero-Beaumont5 and Bruce Cronstein6, 1Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, 2Bone and Joint Research Unit, Fundación Jiménez Díaz UAM, Madrid, Spain, 3Bone and Joint Research Unit, IIS-Fundacion Jimenez Díaz UAM, Madrid, Spain, 4Bone and Joint Research Unit, IIS-Fundación Jimenez Días UAM, Madrid, Spain, 5Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, 6Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Adenosine receptors, bone disease, mouse model and osteoclasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Biology and Pathology of Bone and Joint - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Human Immunodeficiency Virus (HIV) infection devastates the immune system but also affects tissues and organs such as kidney, liver, central nervous system, heart and bone. Bone alterations have been observed in HIV disease for nearly two decades, in particular a higher risk of low bone mineral density (BMD) and fragility fractures. Treatment of patients with tenofovir alone or in combination (as part of HAART), leads to changes in bone catabolism markers and significant reductions in BMD in children and young adults. Tenofovir is taken up by cells and phosphorylated; tenofovir-phosphate inhibits HIV-reverse transcriptase by mimicking AMP. We have recently found that tenofovir inhibits Pannexin-1/Connexin-43-mediated ATP release from cells and decreases extracellular adenosine levels and fibrosis in murine models. As adenosine and ATP are key regulators of bone homeostasis, we determined whether tenofovir directly affects bone by an adenosine- or ATP-dependent mechanism.

Methods:  M-CSF/RANKL-induced osteoclast (OC) and stimulated osteoblast (OB) differentiation were studied in primary murine bone marrow culture as the number of TRAP-positive or Alizarin Red-positive cells, respectively, after challenge with tenofovir (1nM-100mM) alone or in combination with dipyridamole (1nM-100mM), an agent that increases extracellular adenosine by blocking cellular adenosine uptake. Pannexin-1 and Connexin-43 expression were permanently knocked down by lentiviral infection with appropriate shRNA or scrambled shRNA and these cells were induced to differentiate into OC by RANKL. Male C57Bl/6 (WT), A2AKO and A2BKO mice received tenofovir 75mg/Kg/day for 4 weeks. Double labelling of bone with calcein (15mg/Kg)/Alizarin Red (30mg/Kg) was performed and long bones prepared for mCT and histology.

Results:  There was a dose-dependent increase in OC differentiation after treatment with Tenofovir (EC50=44.5nM), that was reversed by dipyridamole (IC50=0.3µM). Moreover, tenofovir inhibited OB differentiation (IC50=0.4µM) which was also reversed by dipyridamole (EC50=10nM). When both Pannexin-1 and Connexin-43 were absent, tenofovir did not increase OC number. Tenofovir treatment reduced bone formation in WT-mice (49±8µm vs 110±7µm untreated p<0.0005) but not in A2AKO (72±6µm vs 71±5µm untreated, p=ns) and A2BKO mice (64±8µm vs 86±9µm untreated, p=ns). mCT revealed decreased BMD and both cortical and trabecular bones were affected. TRAP-staining showed increased OCs in vivo in tenofovir-treated WT mice (21±1 vs 16±1 OC/hpf in untreated, p<0.005). There are increased osteoclasts in A2AKO mice and this was unaffected by tenofovir treatment (24±1 OC/hpf, vs 22±1 OC/hpf in untreated p=ns) and osteoclast number in A2BKO mice was unchanged (19±1 OC/hpf, vs 18±1 OC/hpf in untreated, p=ns). Similar results were obtained for Cathepsin K.

Conclusion:  These results indicate that tenofovir enhances osteoclast differentiation and inhibits osteoblast differentiation by an adenosine-dependent mechanism and suggests that treatment with agents that increase local adenosine concentrations, like dipyridamole, might prevent bone loss following tenofovir treatment.


Disclosure: A. Mediero, CP15/0053, 2, 9,Patent for the use of adenosine A2AR agonists to prevent prosthesis loosening. Patent on the use of Antibodies against Netrin-1 for the treatment of bone diseases., 9; P. Llamas, None; S. Portal-Nuñez, None; R. Largo, None; G. Herrero-Beaumont, None; B. Cronstein, Canfite Pharma, 1,Celgene, AstraZeneca, Takeda, 2,Revive Therapeutics, 5,Always hopeful, 9.

To cite this abstract in AMA style:

Mediero A, Llamas P, Portal-Nuñez S, Largo R, Herrero-Beaumont G, Cronstein B. Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tenofovir-a-nucleoside-analog-reverse-transcriptase-inhibitor-for-treatment-of-hiv-promotes-osteoclast-differentiation-and-decreases-osteoblast-formation-by-a-mechanism-depending-on-atp-release-and/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tenofovir-a-nucleoside-analog-reverse-transcriptase-inhibitor-for-treatment-of-hiv-promotes-osteoclast-differentiation-and-decreases-osteoblast-formation-by-a-mechanism-depending-on-atp-release-and/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology